{
    "clinical_study": {
        "@rank": "8228", 
        "acronym": "V-shoRT-R3", 
        "arm_group": [
            {
                "arm_group_label": "SCRT", 
                "arm_group_type": "Active Comparator", 
                "description": "short course radiotherapy (SCRT) alone 25 Gy in 5 fractions over one week."
            }, 
            {
                "arm_group_label": "V-SCRT", 
                "arm_group_type": "Active Comparator", 
                "description": "Valproic acid (V) + short course radiotherapy"
            }, 
            {
                "arm_group_label": "C-SCRT", 
                "arm_group_type": "Active Comparator", 
                "description": "capecitabine (C) + short course radiotherapy"
            }, 
            {
                "arm_group_label": "VC-SCRT", 
                "arm_group_type": "Active Comparator", 
                "description": "valproic acid + capecitabine + short course radiotherapy"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to first determine the maximum tolerated dose of capecitabine\n      given alone or in combination with valproic acid during preoperative short-course\n      radiotherapy (Phase 1). The next part of the study (Phase 2)will explore whether the\n      addition of valproic acid or the addition of capecitabine to short-course radiotherapy,\n      before optimal radical surgery might increase the pathologic complete tumor regression rate\n      in patients with low-moderate risk rectal cancer."
        }, 
        "brief_title": "Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Rectal Neoplasms", 
                "Colorectal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        \u2022 Patients with histologically confirmed diagnosis of adenocarcinoma of rectum falling\n        into one of the following categories: T2N0 located at <2 cm from anal verge T2N1 or\n        T3N0-N1, located at >5 cm and <12 cm from anal verge and infiltration of perirectal fat\n        for <5 mm from mesorectal fascia (MRF) evaluated by MRI.\n\n          -  Age \u226518 and \u2264 70\n\n          -  ECOG Performance Status \u22641\n\n          -  Effective contraception for both male and female patients if the risk of conception\n             exist\n\n          -  Signed written informed consent\n\n        Exclusion Criteria:\n\n          -  Any previous treatment for rectal cancer\n\n          -  Previous pelvic radiotherapy\n\n          -  Presence of metastatic disease\n\n          -  Recurrent rectal tumor\n\n          -  Patient with Familial Adenomatosis Polyposis (FAP) or Hereditary Non-Polyposis\n             Colorectal Cancer (HNPCC)\n\n          -  History of inflammatory bowel disease or active disease\n\n          -  Any concurrent malignancy except for adequately treated basocellular carcinoma of the\n             skin or in situ carcinoma of  cervix uteri. Patients with a previous malignancy but\n             without evidence of disease for 5 years will be allowed to enter the trial.\n\n          -  Neutrophils < 2000/mm3 or platelets < 100.000/ mm3 or haemoglobin <9 gr/dl.\n\n          -  Creatinine levels indicating renal clearance of <50 ml/min\n\n          -  GOT and/or GPT > 2.5 time the UNL and/or bilirubin >1.5 time the upper-normal limits\n             (UNL)\n\n          -  Significant cardiovascular comorbidity (e.g. myocardial infarction, superior vena\n             cava [SVC] syndrome, patients with an ejection fraction of <50%) or presence of\n             cardiac disease that in the opinion of the Investigator increases the risk of\n             ventricular arrhythmia.\n\n          -  History of arrhythmia (multifocal premature ventricular contractions [PVCs],\n             bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation)\n             which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained\n             ventricular tachycardia.\n\n          -  Patients with long QT-syndrome or QTc interval duration > 480 msec or concomitant\n             medication with drugs prolonging QTc (see list in the appendix)\n\n          -  Known dihydropyrimidine dehydrogenase (DPD) deficiency\n\n          -  HIV positive patients\n\n          -  Patients who cannot take oral medication, who require intravenous alimentation, have\n             had prior surgical procedures affecting absorption, or have active peptic ulcer\n             disease.\n\n          -  Known or suspected hypersensitivity to any of the study drugs.\n\n          -  Patient who have had prior treatment with an HDAC inhibitor and patients who have\n             received compounds with HDAC inhibitor-like activity, such as valproic acid.\n\n          -  Concurrent uncontrolled medical conditions that might contraindicate study drugs.\n\n          -  Major surgical procedure, within 28 days prior to study treatment start.\n\n          -  Pregnant or lactating women.\n\n          -  Women of childbearing potential with either a positive or no pregnancy test at\n             baseline (NB. Postmenopausal women must have been amenorrheic for at least 12 months\n             to be considered of non-childbearing potential.\n\n          -  Sexually active males and females (of childbearing potential) unwilling to practice\n             contraception during the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "152", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01898104", 
            "org_study_id": "V-shoRT-R3", 
            "secondary_id": "2012-002831-28"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "SCRT", 
                    "V-SCRT", 
                    "C-SCRT", 
                    "VC-SCRT"
                ], 
                "description": "25 Gy in 5 fractions over 1 week", 
                "intervention_name": "preoperative radiation therapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": [
                    "V-SCRT", 
                    "VC-SCRT"
                ], 
                "intervention_name": "Valproic Acid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "C-SCRT", 
                    "VC-SCRT"
                ], 
                "intervention_name": "Capecitabine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Valproic Acid", 
                "Capecitabine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "rectal", 
            "low risk", 
            "moderate risk"
        ], 
        "lastchanged_date": "January 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Napoli", 
                    "country": "Italy"
                }, 
                "name": "Istituto Nazionale Tumori Fondazione G. Pascale"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "4", 
        "official_title": "Phase 1/2 Study of Valproic Acid and Short-course Radiotherapy Plus Capecitabine as preoperatIve Treatment in Low-moderate Risk Rectal Cancer", 
        "other_outcome": [
            {
                "description": "description of predictive role of early tumor metabolic changes measured by PET scan", 
                "measure": "evaluation of predictive factors", 
                "safety_issue": "No", 
                "time_frame": "2  months"
            }, 
            {
                "description": "descriptive exploratory analyses", 
                "measure": "predictive and prognostic factors of tumor and circulating cells", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }
        ], 
        "overall_contact": {
            "email": "avalloneantonio@libero.it", 
            "last_name": "Antonio Avallone, M.D.", 
            "phone": "+39 081 5903629"
        }, 
        "overall_contact_backup": {
            "email": "marilina.piccirllo@usc-intnapoli.net", 
            "last_name": "Maria Carmela Piccirillo, M.D.", 
            "phone": "+39 081 5903571"
        }, 
        "overall_official": {
            "affiliation": "National Cancer Institute, Naples", 
            "last_name": "Antonio Avallone, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Phase 1 primary objective", 
                "measure": "maximum tolerated dose of capecitabine, given alone or in combination with valproic acid", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 weeks"
            }, 
            {
                "description": "evaluated at definitive surgery, planned 8 weeks after the end of radiotherapy, in all the study arms of Phase 2", 
                "measure": "number of patients with complete pathological tumor regression", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01898104"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "number of patients alive with disease progression", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "measure": "number of patients with pathologic complete response", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }, 
            {
                "measure": "changes in quality of life from baseline", 
                "safety_issue": "No", 
                "time_frame": "up to 3 months"
            }
        ], 
        "source": "National Cancer Institute, Naples", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute, Naples", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}